American Association for Cancer Research
00085472can183842-sup-213352_2_supp_5340316_pm6gz5.pdf (341.21 kB)

Figure S5 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Download (341.21 kB)
journal contribution
posted on 2023-03-31, 01:46 authored by Dalong Cao, Zihao Qi, Yangyang Pang, Haoran Li, Huyang Xie, Junlong Wu, Yongqiang Huang, Yao Zhu, Yijun Shen, Yiping Zhu, Bo Dai, Xin Hu, Dingwei Ye, Ziliang Wang

Influence of RORC on the growth and proliferation of bladder cancer in vivo


National Natural Science Foundation of China

Youth Foundation of Shanghai



Retinoic acid–related orphan receptor C (RORC) is a member of the nuclear orphan receptor family and performs critical regulatory functions in cell proliferation, metastasis, and chemoresistance in various types of malignant tumors. Here we showed that expression of RORC is lost in tumor tissues of bladder cancer patients. Enhanced expression of RORC suppressed cell proliferation and glucose metabolism and increased cisplatin-induced apoptosis in vitro and in vivo. RORC bound the promoter region of programmed death ligand-1 (PD-L1) and negatively regulated PD-L1 expression. PD-L1 directly interacted with integrin β6 (ITGB6) and activated the ITGB6/FAK signaling pathway. RORC prevented the nuclear translocation of STAT3 via suppression of the PD-L1/ITGB6 signaling pathway, which further inhibited bladder cell proliferation and glucose metabolism and increased cisplatin-induced apoptosis. These findings reveal that RORC regulates bladder cancer cell proliferation, glucose metabolism, and chemoresistance by participating in the PD-L1/ITGB6/STAT3 signaling axis. Moreover, this new understanding of PD-L1 signaling may guide the selection of therapeutic targets to prevent tumor recurrence. These findings suggest that RORC-mediated regulation of a PD-L1/ITGB6/FAK/STAT3 signaling axis in bladder cancer provides several potential therapeutic targets to prevent tumor progression.

Usage metrics

    Cancer Research



    Ref. manager